Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Two new hemoglobin variants: Hb Brem-sur-Mer [beta9(A6)Ser-->Tyr] and Hb Passy [alpha81(F2)Ser-->Pro (alpha2)].

Philippe Lacan1, Mathieu Moreau, Michel Becchi

  • 1Unité de Pathologie Moléculaire, Fédération de Biochimie et de Biologie Spécialisée, Hôpital Edouard Herriot, Lyon Cedex 03, France.

Hemoglobin
|March 17, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External Beam Radiotherapy Primes PDL1-Targeted Radionuclide Therapy in Preclinical Colorectal Cancer Model.

International journal of radiation oncology, biology, physics·2026
Same author

Canadian family physician Medecin de famille canadien·2026
Same author

Health care crisis: looking beyond the obvious: Part 3: Roadmap for an equitable and sustainable health care system.

Canadian family physician Medecin de famille canadien·2026
Same author

Understanding the Factors Explaining the Growing Use of Medical Assistance in Dying in Québec: Protocol for an Interdisciplinary Mixed Methods and Multimethods Study.

JMIR research protocols·2026
Same author

SPECT/NIR Fluorescence Bimodal Use of Aza-BODIPY Probe Coupled with Cetuximab for Detection of Cancer: Proof of Concept on a Preclinical Head and Neck Squamous Cell Carcinoma Model.

Journal of medicinal chemistry·2026
Same author

Management of potentially inappropriate life-sustaining therapies: a survey of Quebec intensivists.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2026

Two novel hemoglobin variants, Hb Brem-sur-Mer and Hb Passy, were identified. Hb Passy, affecting the alpha2-globin gene, was associated with microcytosis and hypochromia, suggesting potential alpha-thalassemia.

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • Hemoglobin (Hb) variants are crucial in understanding red blood cell disorders.
  • Identification and characterization of new Hb variants contribute to genetic diagnostics and disease understanding.

Purpose of the Study:

  • To describe two newly discovered hemoglobin variants: Hb Brem-sur-Mer and Hb Passy.
  • To characterize these variants using molecular and biochemical techniques.
  • To investigate the clinical and hematological implications of these variants.

Main Methods:

  • DNA sequencing was employed to identify the genetic mutations.
  • Mass spectrometry (MS) was utilized for protein-level characterization.
  • Hematological parameters were assessed in carriers.

Related Experiment Videos

Main Results:

  • Hb Brem-sur-Mer involves a Serine to Tyrosine substitution at beta9(A6) in the beta-globin gene.
  • Hb Passy involves a Serine to Proline substitution at alpha81(F2) in the alpha2-globin gene.
  • Hb Passy carriers exhibited microcytosis and hypochromia, indicating hematological abnormalities.

Conclusions:

  • The identified mutations represent novel hemoglobin variants.
  • The alpha81(F2)Pro substitution in Hb Passy may induce alpha-thalassemia, even without co-existing alpha-thalassemic mutations.
  • Further investigation is warranted to fully elucidate the pathogenic mechanisms of Hb Passy.